A venture-backed Canadian biotechnology industry is in its infancy, but faced with hostile capital markets, start-ups need clear exit plans. Consolidation's already started.

Since the mid-1950's getting "shots" has been a source of childhood terror. Now, small companies are looking at ways to deliver vaccines through the oral or nasal mucosa, or using needle-free skin delivery systems to take advantage of immune cells within the skin.